20-F: Sol-Gel Technologies Ltd. Files 20-F Annual Report, Details Financial Performance and Strategic Developments

Sol-Gel Technologies Ltd. releases its 20-F filing, outlining financial data, strategic initiatives, and key developments for the fiscal year ended December 31, 2023.

Summary

• Sol-Gel Technologies Ltd. has released its 20-F filing, reporting a net loss of $27.2 million in 2023 and an accumulated deficit of $220.3 million as of December 31, 2023.
• The company is focused on dermatology with approved products Twyneo and Epsolay, and is developing SGT-610 for Gorlin syndrome and SGT-210 for hyperkeratinization disorders.
• Sol-Gel relies on partnerships with Galderma for U.S. commercialization of Twyneo and Epsolay, and Searchlight Pharma for Canadian commercialization.
• The company purchased assets related to SGT-610 from PellePharm in January 2023 for an upfront payment of $4 million, with potential milestone and royalty payments.
• Sol-Gel has begun screening patients for its Phase 3 study of SGT-610, with results expected by the end of 2025.
• The company is developing SGT-210 for rare hyperkeratinization disorders and expects to initiate a Phase 1 clinical trial during H1 2024.
• Sol-Gel is also developing a generic program in collaboration with Padagis.
• The company's headquarters, manufacturing, and significant operations are located in Israel, which may be affected by political, economic, and military conditions.
• Sol-Gel is subject to healthcare regulatory laws, data protection, privacy and security laws, and environmental, health and safety regulations.
• The company is a controlled company with M. Arkin Dermatology Ltd. holding approximately 58% of the voting power.
• Sol-Gel believes it was a passive foreign investment company (PFIC) for the 2023 taxable year, which could have adverse tax consequences for U.S. shareholders.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has approved products and ongoing development programs, it is also facing significant losses, competition, and risks related to its operations and the regulatory environment. The sentiment is cautiously negative.

Positives

• The company has two FDA-approved products, Twyneo and Epsolay, generating revenue through licensing agreements.
• SGT-610 has received orphan drug and breakthrough therapy designations, potentially leading to market exclusivity and expedited regulatory review.
• The company has a proprietary silica-based microencapsulation technology platform.
• The company has a business continuity plan in place.
• The company has a policy for recovery of erroneously awarded compensation.

Negatives

• The company reported a net loss of $27.2 million in 2023 and has an accumulated deficit of $220.3 million.
• The company is dependent on third parties for commercialization, manufacturing, and clinical trials.
• The company is subject to intense competition in the dermatology market.
• The company is exposed to potential product liability claims.
• The company is exposed to risks associated with international manufacturing operations.
• The company believes it was a passive foreign investment company (PFIC) for the 2023 taxable year, which could have adverse tax consequences for U.S. shareholders.

Risks

• The company may need substantial additional funding to pursue its business objectives.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company may find it difficult to enroll patients in its clinical trials.
• Twyneo, Epsolay, and the company's product candidates, if approved, may fail to achieve broad physician adoption and market acceptance.
• The company's business and operations may be adversely affected by political, economic, and military conditions in Israel.
• The company may be subject to claims for remuneration or royalties for assigned service invention rights by its employees.
• The company may be subject to risk as a result of international manufacturing operations.
• The company may be subject to risk as a result of international manufacturing operations.
• The company may be subject to risk as a result of international manufacturing operations.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through clinical trials and seeks regulatory approval.

Industry Context

The facial aesthetic market, particularly for acne and rosacea treatments, is highly competitive and dynamic, with several large and experienced companies.

Comparison to Industry Standards

• The company's competitors include Bausch Health Companies, Inc., Galderma S.A., Almirall, LLC and Sun Pharmaceutical Industries Ltd.
• These competitors have greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities.

Related Party Transactions

• M. Arkin Dermatology Ltd. is the controlling shareholder of the company.
• The company entered into a subscription agreement with Arkin Dermatology Ltd. for a private placement of ordinary shares and warrants.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by cost-saving measures, including workforce reductions.
• Patients may benefit from the development of new treatments for dermatological conditions.
• The company's suppliers and creditors may be affected by its financial performance and ability to meet its obligations.

Next Steps

• Complete Phase III clinical study of SGT-610.
• Conduct Phase I clinical studies of SGT-210 and continue the research and development of other future investigational product candidates.
• Seek regulatory approvals for any product candidate that successfully completes clinical development.
• Establish commercial manufacturing capabilities through one or more contract manufacturing organizations to commercialize approved products.
• Continue the development, bioequivalence and other studies required for abbreviated new drug application, or ANDA, submissions for generic product candidates.
• Seek new drug candidates and expand the company's disease portfolio.
• Maintain, expand and protect the company's intellectual property portfolio.
• Seek to enhance the company's technology platform.

Key Dates

Keywords

Sol-Gel Technologies, dermatology, Twyneo, Epsolay, SGT-610, SGT-210, Gorlin syndrome, hyperkeratinization, clinical trials, licensing agreements, financial results, pharmaceutical